Statistik Dasar
| CIK | 1873875 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Incannex Healthcare Limited
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar kronologis Pengajuan SEC yang lengkap, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41106 Incannex H |
|
| May 14, 2026 |
Exhibit 99.1 Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea Major operational milestone achieved as Incannex advances late-stage development of IHL-42X, with all clinical sites identified and trial infrastructure activated MELBOURNE, Australia and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-st |
|
| May 14, 2026 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| May 12, 2026 |
Exhibit 99.1 Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development Recognition highlights strong clinical progress and growing global validation of Incannex’s innovative approach to treating obstructive sleep apnea MELBOURNE, Australia and NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), a clin |
|
| May 12, 2026 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| April 22, 2026 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2026 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 22, 2026 |
Exhibit 99.1 Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness Company’s oral synthetic psilocybin program advances within significantly improved regulatory environment MELBOURNE, Australia and NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage bioph |
|
| March 27, 2026 |
Exhibit 99.1 Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position Board initiates buyback activity following period of inactivity, with repurchases executed over the past two trading days Melbourne and New York – 27 March – Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination ther |
|
| March 27, 2026 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2026 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 25, 2026 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2026 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 25, 2026 |
Exhibit 99.1 Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research Company Joins AASM Foundation Corporate Recognition Program and Sponsors Junior Investigator Research Grant as IHL-42X Advances Toward Potential Oral Treatment for Obstructive Sleep Apnea Melbourne and New York – 25 March 2026 – Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stag |
|
| March 18, 2026 |
Exhibit 99.1 Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development Company well-funded to complete DReAMzz Phase 2 study while preserving capital for optimized Phase 3 program Melbourne and New York – 18 March 2026 – Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combinatio |
|
| March 18, 2026 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2026 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 17, 2026 |
Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement Melbourne and New York – March 17, 2026 – Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced that it has regained compliance with the Nasdaq minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2 |
|
| March 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2026 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| March 12, 2026 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT INCANNEX HEALTHCARE inc. Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT INCANNEX HEALTHCARE inc. Warrant Shares: Initial Exercise Date: March 13, 2026 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| March 12, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 12, 2026, between Incannex Healthcare Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| March 12, 2026 |
Exhibit 99.1 Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules NEW YORK and MELBOURNE, Australia, – March 12, 2026 (GLOBE NEWSWIRE) – Incannex Healthcare Inc. (Nasdaq: IHXL), (“Incannex” or the “Company”) a clinical-stage biopharmaceutical company leading the way in developing combination medicines, today announced that it |
|
| March 12, 2026 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT March 12, 2026 Incannex Healthcare Inc. Rialto South Tower Level 23, 525 Collins Street Melbourne, VIC 3008 Australia Attn: Joel Latham Dear Mr. Latham: This letter agreement (the “Agreement”) constitutes the agreement between Curvature Securities, LLC (“Curvature”), as placement agent (the “Placement Agent”) and Incannex Healthcare Inc., a company incorporat |
|
| March 12, 2026 |
Exhibit 99.1 Innovating New Pathways to Relief NASDAQ:IXHL INVESTOR PRESENTATION February 2026 2 Corporate Presentation Legal Disclaimers This presentation of Incannex Healthcare Inc . (" Incannex ") contains "forward - looking statements" within the meaning of the "safe harbor" provisions of the U . S . Private Securities Litigation Reform Act of 1995 . Forward - looking statements are statements |
|
| March 12, 2026 |
Exhibit 99.2 Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 program Melbourne and New York – March 12, 2026 – Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2026 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| March 12, 2026 |
WARRANT TO PURCHASE SHARES OF COMMON STOCK INCANNEX HEALTHCARE INC. Exhibit 4.1 WARRANT TO PURCHASE SHARES OF COMMON STOCK INCANNEX HEALTHCARE INC. Warrant Shares: [●] Initial Exercise Date: March 13, 2026 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| March 12, 2026 |
Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-283028 and 333-288921 Prospectus Supplement (To prospectus dated November 22, 2024) INCANNEX HEALTHCARE INC. 1,997,285 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 2,715 Shares of Common Stock Common Stock Warrants to Purchase Up to 2,000,000 Shares of Common Stock We are offering 1,997,285 shares of our common stock and accomp |
|
| February 25, 2026 |
Exhibit 99.1 Incannex Announces Reverse Stock Split Incannex’s common stock is expected to begin trading on a post-split adjusted basis on February 27, 2026 MELBOURNE, Australia and NEW YORK, USA, February 25, 2026 – Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical cond |
|
| February 25, 2026 |
CERTIFICATE OF AMENDMENT AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION The corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certified that: FIRST: The name of the corporation is Incannex Healthcare Inc. (the “Corporation”). SECOND: The Amended and Restated Certificate of Incorporation of the Corporation, as amended to date, is |
|
| February 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commiss |
|
| February 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41106 Incanne |
|
| January 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2026 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissi |
|
| January 29, 2026 |
Exhibit 99.1 Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board Expands clinical expertise to support disciplined advancement of the PSX-001 program MELBOURNE, Australia and NEW YORK, USA — January 29, 2026 — Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment |
|
| January 22, 2026 |
Exhibit 99.1 Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program Strengthens clinical and regulatory guidance as PSX-001 advances to its next phase of development MELBOURNE, Australia and NEW YORK, USA — January 22, 2026 — Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces the |
|
| January 22, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2026 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissi |
|
| January 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2026 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissi |
|
| January 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2026 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissi |
|
| January 15, 2026 |
Exhibit 99.1 Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards MELBOURNE, Australia and NEW YORK – January 15th, 2026 – (GLOBE NEWSWIRE) – Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has been honor |
|
| January 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2026 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissi |
|
| January 14, 2026 |
Exhibit 99.1 Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026 Company enters 2026 with over $70 million in cash, two positive Phase 2 programs, FDA Fast Track Designation and runway well into 2027 MELBOURNE, Australia and NEW YORK, USA — January 14, 2026 — Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company develo |
|
| December 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commiss |
|
| December 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 3, 2025 |
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA) Exhibit 99.1 Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA) MELBOURNE, Australia and NEW YORK, USA — December 3, 2025 — Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IHL-42X, th |
|
| December 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissi |
|
| November 14, 2025 |
CALCULATION OF FILING FEE TABLES Incannex Healthcare Inc. Table 1: Newly Registered Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Incannex Healthcare Inc. Table 1: Newly Registered Securities Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per share (1) Other 69,541,101 $ 0.3602 $ 25,048,704.58 0 |
|
| November 14, 2025 |
As filed with the Securities and Exchange Commission on November 14, 2025 As filed with the Securities and Exchange Commission on November 14, 2025 REGISTRATION NO. |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41106 Incann |
|
| October 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissi |
|
| October 30, 2025 |
Exhibit 99.1 Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus Company outlines continued progress across clinical, regulatory, and capital initiatives positioning for sustained long-term growth MELBOURNE, Australia and NEW YORK, USA — October 30, 2025 — Incannex Healthcare Inc. (Nasdaq: IXHL)(“Incannex” or the “Company”), a clini |
|
| October 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41106 Incannex Healthcar |
|
| October 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| October 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| October 22, 2025 |
Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement Exhibit 99.1 Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement MELBOURNE, Australia and NEW YORK, USA — October 22 — Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, today announced that it has received an additional 180-calendar-day ext |
|
| October 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissi |
|
| October 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissi |
|
| September 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41106 Incannex Healthcar |
|
| September 29, 2025 |
Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Incannex Healthcare Inc., a Delaware corporation (the “Company”) is a summary only. This summary is subject to the General Corporation Law of the State of Delaware (the “DGCL”) and the complete text of the Company’s Certificate of Incorporation and the Bylaws, each as amended and restated. General Under the |
|
| August 26, 2025 |
Exhibit 99.1 Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder Psi-GAD delivers statistically significant and clinically meaningful improvements across validated measures of anxiety, mood, disability, and quality of life; results establish PSX-001 as a leading psilocybin-assisted therapy in development globally MELBOURNE, Australia |
|
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissio |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissio |
|
| August 22, 2025 |
Incannex Healthcare Authorizes $20 Million Share Repurchase Program Exhibit 99.1 Incannex Healthcare Authorizes $20 Million Share Repurchase Program Melbourne, Australia and New York, USA – August 22 – Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact conditions, today announced that its Board of Directors has authorized a share repurchase pr |
|
| August 8, 2025 |
Exhibit 99.1 Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea Exit interviews and clinical results reinforce strong potential for meaningful improvements in sleep quality, cognitive function, and daily life MELBOURNE, Australia and NEW YORK, USA — August 8 — Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage ph |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| July 31, 2025 |
Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term Exhibit 99.1 Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term Melbourne, Australia, July 31, 2025 – Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”) announced, in response to recent questions it received from a number of its stockholders, that it does not presently intend to use the full capacity available under its at the marke |
|
| July 30, 2025 |
Exhibit 99.1 Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X Statistically and clinically significant improvements across key clinical endpoints; IHL-42X reduced AHI by up to 83% from baseline. IHL-42X demonstrates compelling clinical benefit and an outstanding safety profile that exceeded expectations. NEW YORK and MELBOURNE, Australia, July 30, 2025 – Incannex Heal |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| July 25, 2025 |
Exhibit 99.1 Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo NEW YORK and MELBOURNE, Australia – July 25, 2025 – Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the ap |
|
| July 24, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Incannex Healthcare Inc. |
|
| July 24, 2025 |
Up to $100,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration Nos. 333-283028 and 333-288921 Prospectus Supplement (to Prospectus Supplements dated May 20, 2025, April 7, 2025, and May 28, 2025 to Prospectus dated November 22, 2024) Up to $100,000,000 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) amends and supplements the information in the prospectus, dated November 22, 2024 ( |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| July 24, 2025 |
As filed with the Securities and Exchange Commission on July 24, 2025 As filed with the Securities and Exchange Commission on July 24, 2025 Registration No. |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| June 24, 2025 |
Exhibit 99.1 Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch NEW YORK and MELBOURNE, Australia – June 24, 2025 – Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appo |
|
| June 18, 2025 |
Exhibit 99.1 Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X Top-line results expected July 2025 as development of first-in-class OSA drug advances NEW YORK and MELBOURNE, Australia – June 18, 2025 – Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-i |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| June 17, 2025 |
Exhibit 99.1 Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy Expanded platform improves access, scales operations, and advances Incannex’s position in next-generation mental health treatment NEW YORK and MELBOURNE, Australia – June 17, 2025 – Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| June 12, 2025 |
Exhibit 99.1 Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution Capital structure streamlined and potential dilution from Series A Warrants eliminated ahead of key Phase 2 clinical milestones NEW YORK and MELBOURNE, Australia – June 12, 2025 – Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical compa |
|
| June 4, 2025 |
As filed with the Securities and Exchange Commission on June 4, 2025 As filed with the Securities and Exchange Commission on June 4, 2025 REGISTRATION NO. |
|
| June 4, 2025 |
AMENDMENT NO. 1 INCANNEX HEALTHCARE INC. 2023 EQUITY INCENTIVE PLAN Exhibit 99.1 AMENDMENT NO. 1 TO INCANNEX HEALTHCARE INC. 2023 EQUITY INCENTIVE PLAN In accordance with those certain resolutions adopted by the Board of Directors and stockholders of Incannex Healthcare Inc., a Delaware corporation (the “Company”), the Incannex Healthcare Inc. 2023 Equity Incentive Plan (the “Plan”) is hereby amended as follows: 1. Section 5(b) of the Plan is hereby amended and re |
|
| June 4, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Incannex Healthcare Inc. |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission F |
|
| June 3, 2025 |
Exhibit 99.1 Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program NEW YORK and MELBOURNE, Australia – June 3, 2025 – Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company leading the way in developing oral combination medic |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission F |
|
| May 29, 2025 |
Exhibit 99.1 Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance Streamlined U.S.-only study design builds on Phase 2 momentum for IHL-42X in obstructive sleep apnea NEW YORK and MELBOURNE, Australia – May 29, 2025 – Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing novel combination therapies, today announced |
|
| May 28, 2025 |
AMENDMENT NO. 1 INCANNEX HEALTHCARE INC. 2023 EQUITY INCENTIVE PLAN Exhibit 10.2 AMENDMENT NO. 1 TO INCANNEX HEALTHCARE INC. 2023 EQUITY INCENTIVE PLAN In accordance with those certain resolutions adopted by the Board of Directors and stockholders of Incannex Healthcare Inc., a Delaware corporation (the “Company”), the Incannex Healthcare Inc. 2023 Equity Incentive Plan (the “Plan”) is hereby amended as follows: 1. Section 5(b) of the Plan is hereby amended and re |
|
| May 28, 2025 |
Incannex healthcare INC. COMMON STOCK Amended and Restated SALES AGREEMENT Exhibit 1.1 Incannex healthcare INC. COMMON STOCK Amended and Restated SALES AGREEMENT May 27, 2025 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Curvature Securities LLC 39 Main Street, Suite 100 Chatham, NJ 07928 Ladies and Gentlemen: Incannex Healthcare Inc., a Delaware corporation (the “Company”), and A.G.P./Alliance Global Partners (“A.G.P.”) are parties to that certai |
|
| May 28, 2025 |
Up to $50,000,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-283028 Prospectus Supplement (to Prospectus Supplements dated May 20, 2025 and April 7, 2025, to Prospectus dated November 22, 2024) Up to $50,000,000 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) amends and supplements the information in the prospectus, dated November 22, 2024 (the “Prospectus”), filed with t |
|
| May 28, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INCANNEX HEALTHCARE INC. Incannex Healthcare Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The Amended and Restated Certificate of Incorporation of the Corporation is hereby amended by deleting Section 4.1 of Arti |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission F |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission F |
|
| May 28, 2025 |
Exhibit 99.1 Incannex Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of Key Phase 2 Results Melbourne, Australia and New York, USA – May 28, 2025 – Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, today announced that it |
|
| May 28, 2025 |
Exhibit 10.1 May 27, 2025 Incannex Healthcare Inc. 8 Century Circuit, Suite 105 Norwest Sydney, NSW 2153, Australia Attention: Joel Latham Re: Letter Agreement Ladies and Gentlemen: Reference is made to (i) that certain Registration Rights Agreement (the “Registration Rights Agreement”), dated as of March 7, 2025, by and between Incannex Healthcare, Inc. (the “Company”) and the undersigned (the “I |
|
| May 20, 2025 |
Exhibit 99.1 Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution Raises $12.5M via ATM to Strengthen Shareholder Position Ahead of IHL-42X Phase 2 Data NEW YORK and MELBOURNE, Australia – May 20, 2025 – Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company pione |
|
| May 20, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission F |
|
| May 20, 2025 |
Up to $2,514,214 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-283028 Prospectus Supplement (to Prospectus Supplement dated April 7, 2025, to Prospectus dated November 22, 2024) Up to $2,514,214 Shares of Common Stock This prospectus supplement (this “Prospectus Supplement”) amends and supplements the information in the prospectus, dated November 22, 2024 (the “Prospectus”), filed with the Securities and E |
|
| May 20, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission F |
|
| May 16, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission F |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| May 16, 2025 |
Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants Exhibit 99.1 Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants NEW YORK and MELBOURNE, Australia, May 16, 2025 (GLOBE NEWSWIRE) – Incannex Healthcare Inc. (Nasdaq: IXHL), (“Incannex”), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, announced its entry on May 15, 2025 into agreements with the outstanding holders of i |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission F |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission F |
|
| May 15, 2025 |
Exhibit 1.1 May 15, 2025 Incannex Healthcare Inc. 8 Century Circuit, Suite 105 Norwest Sydney, NSW 2153, Australia Attention: Joel Latham Re: Letter Agreement Ladies and Gentlemen: Reference is made to (i) that certain Registration Rights Agreement (the “Registration Rights Agreement”), dated as of March 7, 2025, by and between Incannex Healthcare, Inc. (the “Company”) and the undersigned (the “In |
|
| May 15, 2025 |
Exhibit 99.1 Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates NEW YORK and MELBOURNE, Australia, May 15, 2025 (GLOBE NEWSWIRE) - Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financial results and provided |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41106 Incannex H |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission F |
|
| May 14, 2025 |
Exhibit 99.1 Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) ● Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA. ● End-of-study follow-up assessments on track for completion by May 17, 2025. ● Topline results expected in July 2025. NEW YORK and MELBOUR |
|
| April 29, 2025 |
April 29, 2025 Joel Latham Chief Executive Officer Incannex Healthcare Inc. Suite 105, 8 Century Circuit Northwest NSW, 2153 Australia Re: Incannex Healthcare Inc. Preliminary Proxy Statement on Schedule 14A Filed March 18, 2025 File No. 001-41106 Dear Joel Latham: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and ad |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 28, 2025 |
Incannex Healthcare Inc. 75,902,171 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-286047 PROSPECTUS Incannex Healthcare Inc. 75,902,171 Shares of Common Stock This prospectus relates to the offer and sale by the selling stockholders named in this prospectus, and any pledgee, donee, transferee or other successor in interest, of up to an aggregate of 75,902,171 shares (the “Shares”) of common stock, par value $0.0001 per share |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| April 24, 2025 |
INCANNEX HEALTHCARE INC. SUITE 105, 8 CENTURY CIRCUIT NORWEST, NSW 2153 AUSTRALIA INCANNEX HEALTHCARE INC. SUITE 105, 8 CENTURY CIRCUIT NORWEST, NSW 2153 AUSTRALIA April 24, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drory Re: Incannex Healthcare Inc. Registration Statement on Form S-1/A File No. 333-286047 (the “Registration Statement”) Acceleration Request Ladies and Gentlem |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| April 16, 2025 |
As filed with the Securities and Exchange Commission on April 16, 2025 As filed with the Securities and Exchange Commission on April 16, 2025 Registration No. |
|
| April 16, 2025 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Incannex Healthcare Inc. |
|
| April 16, 2025 |
3580 Camel Mountain Road Suite 300 San Diego, CA 92130 858 314 1500 mintz.com April 16, 2025 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Jason Drory Laura Crotty Re: Incannex Healthcare Inc. Registration Statement on Form S-3 Filed March 24, 2025 File No. 333-286047 Dear Mr. |
|
| April 7, 2025 |
Exhibit 10.1 Incannex healthcare INC. COMMON STOCK SALES AGREEMENT April 7, 2025 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Incannex Healthcare Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows: 1. Issuance and Sale of Shares. The Company agree |
|
| April 7, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| April 7, 2025 |
Up to $16,768,099 of Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-283028 Prospectus Supplement (To Prospectus dated November 22, 2024) Up to $16,768,099 of Shares of Common Stock We have entered into a Sales Agreement (the “Sales Agreement”), with A.G.P./Alliance Global Partners (“A.G.P.” or “Sales Agent”) relating to the sale of shares of our common stock, par value $0.0001 per share, offered by this prospec |
|
| April 3, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| April 3, 2025 |
Exhibit 99.1 Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) Topline Phase 2 clinical data expected in the first half 2025 NEW YORK and MELBOURNE, Australia, April 3 2025 (GLOBE NEWSWIRE) - Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the |
|
| April 2, 2025 |
April 2, 2025 Joel Latham Chief Executive Officer Incannex Healthcare Inc. Suite 105, 8 Century Circuit Northwest NSW 2153 Australia Re: Incannex Healthcare Inc. Registration Statement on Form S-3 Filed March 24, 2025 File No. 333-286047 Dear Joel Latham: We have conducted a limited review of your registration statement and have the following comments. Please respond to this letter by amending you |
|
| April 2, 2025 |
April 2, 2025 Joel Latham Chief Executive Officer Incannex Healthcare Inc. Suite 105, 8 Century Circuit Northwest NSW 2153 Australia Re: Incannex Healthcare Inc. Preliminary Proxy Statement on Schedule 14A Filed March 18, 2025 File No. 001-41106 Dear Joel Latham: We have reviewed your filing and have the following comments. Please respond to this letter within ten business days by providing the re |
|
| March 24, 2025 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Incannex Healthcare Inc. |
|
| March 24, 2025 |
As filed with the Securities and Exchange Commission on March 24, 2025 As filed with the Securities and Exchange Commission on March 24, 2025 Registration No. |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 10, 2025 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 7, 2025, between Incannex Healthcare Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission |
|
| March 10, 2025 |
Form of Placement Agency Agreement Exhibit 10.3 Placement Agency Agreement March 7, 2025 Incannex Healthcare Inc. Attn: Joel Latham 8 Century Circuit, Suite 105 Northwest Sydney, NSW 2153, Australia Dear Mr. Latham: This letter (the “Agreement”) constitutes the agreement between R.F. Lafferty & Co., Inc. (the “Placement Agent”) and Incannex Healthcare Inc., a Delaware corporation (the “Company”), that the Placement Agent shall serv |
|
| March 10, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 10, 2025 |
Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| March 10, 2025 |
Exhibit 99.1 Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules Funds to support the advancement of Incannex’s IHL-42X Phase 2/3 Obstructive Sleep Apnea (OSA) clinical program through U.S. Phase 2 completion, topline readout, and its expansion into a global Phase 3 study. NEW YORK and MELBOURNE, Australia, March 7, 2025 (GLOBE NEWS |
|
| March 10, 2025 |
Form of Registration Rights Agreement Exhibit 10.2 INCANNEX HEALTHCARE INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 7 2025, by and between Incannex Healthcare Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pur |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41106 Incanne |
|
| February 14, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commiss |
|
| February 14, 2025 |
Exhibit 99.1 Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates ● Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submission ● New OSA Clinical Advisory Board Announced; Appoints Dr. Alison Wimms, Representing ResMed NEW YORK and MELBOURNE, Australia, February 14, 202 |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissi |
|
| February 4, 2025 |
Exhibit 99.1 Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board Dr. Wimms brings extensive industry and clinical development experience in sleep medicine innovation NEW YORK and MELBOURNE, Australia, February 4, 2025 (GLOBE NEWSWIRE) - Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissi |
|
| January 23, 2025 |
Exhibit 99.1 Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea ● Demonstrated bioavailability of IHL-42X, Incannex’s proprietary combination formulation, confirming delivery of both dronabinol and acetazolamide ● Achieved similar PK and equivalent total drug exposure levels o |
|
| January 10, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2025 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissio |
|
| December 11, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commiss |
|
| December 6, 2024 |
Incannex Healthcare Inc. 61,389,758 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-283025 PROSPECTUS Incannex Healthcare Inc. 61,389,758 Shares of Common Stock This prospectus relates to the offer and sale by the selling stockholders named in this prospectus, and any pledgee, donee, transferee or other successor in interest, of up to 61,389,758 shares (the “Shares”) of common stock, par value $0.0001 per share, of Incannex He |
|
| December 4, 2024 |
INCANNEX HEALTHCARE INC. SUITE 105, 8 CENTURY CIRCUIT NORWEST, NSW 2153 AUSTRALIA INCANNEX HEALTHCARE INC. SUITE 105, 8 CENTURY CIRCUIT NORWEST, NSW 2153 AUSTRALIA December 4, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Stacey Gama Re: Incannex Healthcare Inc. Registration Statement on Form S-1/A File No. 333-283025 (the “Registration Statement”) Acceleration Request Ladies and |
|
| November 26, 2024 |
As filed with the Securities and Exchange Commission on November 26, 2024. As filed with the Securities and Exchange Commission on November 26, 2024. Registration Statement No. 333-283025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INCANNEX HEALTHCARE INC. (Exact name of registrant as specified in its charter) Delaware 2834 93-2403210 |
|
| November 26, 2024 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Incannex Healthcare Inc. |
|
| November 20, 2024 |
INCANNEX HEALTHCARE INC. SUITE 105, 8 CENTURY CIRCUIT NORWEST, NSW 2153 AUSTRALIA INCANNEX HEALTHCARE INC. SUITE 105, 8 CENTURY CIRCUIT NORWEST, NSW 2153 AUSTRALIA November 20, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Stacey Gama Re: Incannex Healthcare Inc. Registration Statement on Form S-3 File No. 333-283028 (the “Registration Statement”) Acceleration Request Ladies and |
|
| November 15, 2024 |
November 15, 2024 Joel Latham Chief Executive Officer Incannex Healthcare Inc. Suite 105, 8 Century Circuit Norwest NSW 2153 Australia Re: Incannex Healthcare Inc. Registration Statement on Form S-3 Filed November 6, 2024 File No. 333-283025 Dear Joel Latham: We have conducted a limited review of your registration statement and have the following comment. Please respond to this letter by amending |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41106 Incann |
|
| November 13, 2024 |
November 13, 2024 Joel Latham Chief Executive Officer Incannex Healthcare Inc. Suite 105, 8 Century Circuit Norwest NSW 2153 Australia Re: Incannex Healthcare Inc. Registration Statement on Form S-3 Filed November 6, 2024 File No. 333-283028 Dear Joel Latham: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) 6 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41106 Incannex Healthcar |
|
| November 6, 2024 |
As filed with the Securities and Exchange Commission on November 6, 2024 As filed with the Securities and Exchange Commission on November 6, 2024 Registration No. |
|
| November 6, 2024 |
Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| November 6, 2024 |
Calculation of Filing Fee Table. EX-FILING FEES 12 ea021980601ex-feeincannex.htm CALCULATION OF FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Incannex Healthcare Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggrega |
|
| November 6, 2024 |
As filed with the Securities and Exchange Commission on November 6, 2024 As filed with the Securities and Exchange Commission on November 6, 2024 Registration No. |
|
| November 6, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| November 6, 2024 |
Exhibit 10.7 GUARANTEE GUARANTEE (the “Guarantee”), dated as of October 14, 2024, by the Guarantors (as defined below) in favor of the Purchasers (as defined below). WHEREAS, Incannex Healthcare Inc., a Delaware corporation (the “Borrower”), is the holder of certain equity interests of the Guarantors; and WHEREAS, pursuant to that certain Security Agreement (defined below), the Borrower is pledgin |
|
| November 6, 2024 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Incannex Healthcare Inc. |
|
| November 6, 2024 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 14, 2024, by and between INCANNEX HEALTHCARE INC., a Delaware corporation (the “Company”), and those certain investors identified on the signature page hereto (together with it permitted assigns, the “Investors”). Capitalized terms used herein and not otherwise defined herein shall have |
|
| November 6, 2024 |
Exhibit 10.4 SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of October 14, 2024 (this “Agreement”), is among Incannex Healthcare Inc., a Delaware corporation (the “Company”), all of the Significant Subsidiaries of the Company as such term is defined in the Purchase Agreement (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”) and the holder of the Company’s 10% |
|
| November 6, 2024 |
Exhibit 4.6 INCANNEX HEALTHCARE INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 2 Section 1.1 Definitions. 2 Section 1.2 Other Definitions. 4 Section 1.3 Incorporation by Reference of Trust Indenture Act. 5 Section 1.4 Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1 Issuable in Series. 5 Section 2.2 Establish |
|
| November 6, 2024 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| November 6, 2024 |
Exhibit 10.6 TRADEMARK SECURITY AGREEMENT THIS TRADEMARK SECURITY AGREEMENT (the “Agreement”) made as of this 14th day of October, 2024, by Incannex Healthcare Pty Ltd (previously Incannex Healthcare Limited), an Australian proprietary limited company (“Grantor”), in favor of each grantee identified on the signature page hereto (herein, “Grantees”): W I T N E S S E T H WHEREAS, Grantor’s direct pa |
|
| November 6, 2024 |
Exhibit 10.5 PATENT SECURITY AGREEMENT THIS PATENT SECURITY AGREEMENT (the “Agreement”) made as of this 14th day of October, 2024, by Incannex Healthcare Pty Ltd, an Australian proprietary limited company (previously Incannex Healthcare Limited) (“Grantor”), in favor of each grantee identified on the signature page hereto (herein, “Grantees”): W I T N E S S E T H WHEREAS, Grantor’s direct parent a |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissi |
|
| October 24, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report October 24, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Ident |
|
| October 24, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is effective as of October 21, 2024 (the “Effective Date”) by and between Incannex Healthcare, Inc. a Delaware corporation (the “Company”), and Lou Barbato (“Employee”). The Company and Employee may hereinafter collectively be referred to the the “Parties,” and individually referred to as a “Party.” 1. Roles and Duties. |
|
| October 24, 2024 |
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer Exhibit 99.1 Date: October 24, 2024 Public Announcement (NASDAQ: IXHL) Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer NEW YORK and MELBOURNE, Australia, October 24, 2024 (GLOBE NEWSWIRE) - Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet |
|
| October 21, 2024 |
Secured Convertible Debenture, dated October 14, 2024 Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| October 21, 2024 |
Common Stock Purchase Warrant, dated October 14, 2024 Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE |
|
| October 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissi |
|
| October 15, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commissio |
|
| October 15, 2024 |
Exhibit 10.1 Facility Agreement – Incannex Incannex Healthcare Pty Ltd ACN 096 635 246 as Borrower Each person listed in Part B of Schedule 1 as a Guarantor FC Credit Pty Ltd ACN 676 254 881 as trustee for SPV 1006-25 Trust ABN 69 780 239 347 as Financier Execution Version Brisbane | Sydney | Canberra Level 32, 25 Martin Place Sydney NSW 2000 GPO Box 462 Sydney NSW 2001 T +61 2 8241 5600 F + 61 2 |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41106 Incannex Healthcar |
|
| September 30, 2024 |
2023 Australian Incentive Sub-Plan Exhibit 10.9 INCANNEX HEALTHCARE INC. 2023 Equity incentive PLAN Subplan for Australian Participants 1. Purpose and Applicability. This Subplan for Australian Participants (the “Australian Subplan”) applies to Employees, Directors, and Consultants of Incannex Healthcare Inc. (the “Company”) and of its Subsidiaries and Affiliates, who are either Australian residents or Australian taxpayers, and who |
|
| September 30, 2024 |
Policy for Recovery of Erroneously Awarded Compensation, adopted on October 5, 2023 Exhibit 97.1 Incannex Healthcare Inc. Policy on Recovery of Erroneously Awarded Incentive Compensation Introduction Incannex Healthcare Inc. (the “Company”) will be listed on Nasdaq and, as such, will be subject to the requirements of the US Securities Exchange Act of 1934 and rules promulgated by the US Securities and Exchange Commission. In 2023, the SEC issued new Rule 10D-1, which requires US |
|
| September 30, 2024 |
Securities Trading Policy, adopted on October 5, 2023 Exhibit 19.1 Incannex Healthcare Inc. Securities Trading Policy 1. Introduction U.S. federal and state laws prohibit buying, selling or making other transfers of securities by persons who have material information that is not generally known or available to the public. These laws also prohibit persons with such material nonpublic information from disclosing this information to others who trade. In |
|
| September 30, 2024 |
Exhibit 21.1 List of Subsidiaries Subsidiary Ownership Jurisdiction Incannex Healthcare Pty Ltd 100 % Victoria, Australia Incannex Pty Ltd 100 % Victoria, Australia Psychennex Pty Ltd 100 % Victoria, Australia APIRx Pharmaceutical USA, LLC 100 % Delaware APIRx Pharmaceuticals Holding BV 100 % IJsselstein, Netherlands Clarion Clinics Group Pty Ltd 100 % Victoria, Australia Clarion Model Clinic Pty |
|
| September 30, 2024 |
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates Exhibit 99.1 Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates ● Announced strategic financing with Arena Investors, providing access to up to $59.0 million USD in gross proceeds to Incannex ● Announced positive top-line results from our Phase 2 proof-of-concept clinical trial of PSX-001, known as the PsiGAD1 study, in which synthetic psilocybin in combi |
|
| September 30, 2024 |
Exhibit 4.2 WARRANT AGENCY AGREEMENT This Warrant Agent Agreement (“Warrant Agreement”) is made as of December 29, 2023, by and among Incannex Healthcare Inc., a Delaware corporation, with offices at 221 Dosoris Lane, Glen Cove, New York 11542 (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate Computershare Trust Company, N.A. a federally chartered |
|
| September 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report September 30, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Ide |
|
| September 10, 2024 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 6, 2024, between Incannex Healthcare Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature page hereto (each, a “Purchaser” and together, the “Purchasers”). Each of the Company and each Purchaser shall individually be referred to herein as |
|
| September 10, 2024 |
Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (this “Agreement”), dated as of September 6, 2024, is made by and between ARENA BUSINESS SOLUTIONS GLOBAL SPC II, LTD (the “Investor”), and INCANNEX HEALTHCARE INC, a Delaware corporation (the “Company”). WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall have the right to issue |
|
| September 10, 2024 |
Incannex Healthcare Inc. Suite 105, 8 Century Circuit Norwest, NSW 2153 Australia Incannex Healthcare Inc. Suite 105, 8 Century Circuit Norwest, NSW 2153 Australia September 10, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-1090 Re: Incannex Healthcare Inc. - Withdrawal of Registration Statement on Form S-1 (File No. 333-280670) Ladies and Gentlemen: Pursuant to Rule 477 under the Securi |
|
| September 10, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commis |
|
| September 10, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commiss |
|
| September 10, 2024 |
Exhibit 99.1 Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors Incannex to Receive Funding of Up to $10 Million in Convertible Notes and $50 Million Equity Line of Credit NEW YORK and MELBOURNE, September 10, 2024 (GLOBE NEWSWIRE) - Incannex Healthcare Inc. (Nasdaq: IXHL), (the “Company” or “Incannex”), a clinical-stage biopharmaceutical company developin |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report August 5, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identif |
|
| August 5, 2024 |
Exhibit 99.1 Date: August 05, 2024 Public Announcement (NASDAQ: IXHL) FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed - Approval from FDA to proceed with 94 patient Phase 2 clinical trial received following review of IND dossier containing information on the clinical trial, as well as safety and quali |
|
| July 30, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report July 30, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identifi |
|
| July 30, 2024 |
Exhibit 99.1 Date: July 30, 2024 Public Announcement (NASDAQ: IXHL) Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X - IHL-42X is a fixed dose combination drug targeting obstructive sleep apnea (OSA), a medical condition with no available registered pharmaceutical treatment for millions of sufferers in the USA alon |
|
| July 17, 2024 |
Exhibit 4.3 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK INCANNEX HEALTHCARE INC. Warrant Shares: Initial Exercise Date: [●], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at an |
|
| July 17, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Incannex Healthcare Inc. |
|
| July 17, 2024 |
Exhibit 4.2 INCANNEX HEALTHCARE INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: Number of Shares of Common Stock: Date of Issuance: [●], 2024 (“Issuance Date”) Incannex Healthcare Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●], the registered holder hereof or its permitte |
|
| July 17, 2024 |
As filed with the Securities and Exchange Commission on July 17, 2024 As filed with the Securities and Exchange Commission on July 17, 2024 Registration No. |
|
| July 17, 2024 |
Form of Warrant Agency Agreement Exhibit 10.10 INCANNEX HEALTHCARE INC. and COMPUTERSHARE INC. and COMPUTERSHARE TRUST COMPANY, N.A., as Warrant Agent Warrant Agency Agreement Dated as of July [●], 2024 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of July [●], 2024 (“Agreement”), between Incannex Healthcare Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Computershare Inc. |
|
| July 17, 2024 |
Form of Securities Purchase Agreement Exhibit 10.9 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2024 (the “Effective Date”), among Incannex Healthcare Inc., a Delaware corporation (the “Company”), and each purchaser identified on Exhibit A attached hereto (each a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in this Ag |
|
| July 3, 2024 |
As filed with the Securities and Exchange Commission on July 3, 2024 As filed with the Securities and Exchange Commission on July 3, 2024 Registration No. |
|
| July 3, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Incannex Healthcare Inc. |
|
| May 30, 2024 |
Exhibit 99.1 Date: May 30, 2024 Public Announcement (NASDAQ: IXHL) Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea NEW YORK, USA and MELBOURNE, Australia, May 30, 2024 (GLOBE NEWSWIRE) - Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing unique medicinal can |
|
| May 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report May 30, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identific |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41106 Incannex Healthcare |
|
| May 7, 2024 |
Exhibit 99.1 Date: May 7, 2024 Public Announcement (NASDAQ: IXHL) Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder MELBOURNE, Australia and NEW YORK, May 7, 2024: Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful |
|
| May 7, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report May 7, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identifica |
|
| April 16, 2024 |
Incannex Healthcare Inc. Quarterly Update, Q1 2024 Exhibit 99.1 Date: April 16, 2024 Public Announcement (NASDAQ: IXHL) Incannex Healthcare Inc. Quarterly Update, Q1 2024 Melbourne, Australia, April 16, 2024 - Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024. Incannex is undertaking var |
|
| April 16, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report April 16, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identif |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commiss |
|
| March 5, 2024 |
Exhibit 10.1 Table of Contents Incannex Healthcare Inc – Executive Employment Contract 27 February 2024 Category Sub Category Page 1. Employment 1.1 Engagement 2 1.2 Employment Commencement Date 2 1.3 Exclusivity 2 1.4 Employment Contract Term 2 2. Employment Duties 2.1 Your Duties 2 2.2 Hours of Work 2 2.3 Reporting Relationship 3 2.4 Work Location 3 2.5 Adherence to Policies & Procedures 3 3. Re |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report February 28, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Iden |
|
| February 28, 2024 |
Exhibit 99.1 Date: February 28, 2024 Public Announcement (NASDAQ: IXHL) Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder Highlights: - PsiGAD1 trial achieves primary endpoint; PsiGAD psilocybin-assisted therapy demonstrated a statistically significant HAM-A reduction of 12.8 points from baseline, representing a 9.2-point |
|
| February 16, 2024 |
Exhibit 99.1 Date: February 16, 2024 Public Announcement (NASDAQ: IXHL) Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation MELBOURNE, Australia and NEW YORK, Feb. 16, 2024: Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to annou |
|
| February 16, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report February 16, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Iden |
|
| February 14, 2024 |
Employment Agreement between Incannex Healthcare Limited and Joseph Swan, dated November 8, 2021 Exhibit 10.14 Table of Contents lncannex Healthcare Limited - Employment Contract 08 November 2021 Category Sub Category Page 1. Emplovment 1.1 Engagement 2 1.2 Emplovment Commencement Date 2 1.3 Exclusivity 2 1.4 EmPlovment Contract Term 2 2. Emplovment Duties 2.1 Your Duties 2 2.2 Hours of Work 2 2.3 Reportina Relationship 2 2.4 Work Location 2 2.5 Adherence to Policies & Procedures 3 3. Remuner |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41106 Incanne |
|
| February 1, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report February 1, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Ident |
|
| February 1, 2024 |
CLARION CLINICS OPEN FOR PSYCHEDELIC-ASSISTED TREATMENTS Exhibit 99.1 Date: February 1, 2024 Public Announcement (NASDAQ: IXHL) CLARION CLINICS OPEN FOR PSYCHEDELIC-ASSISTED TREATMENTS Highlights: ● Clarion’s Head of Psychiatry, Professor Suresh Sundram, has been approved by the TGA to prescribe MDMA for Post-traumatic Stress Disorder and psilocybin for Treatment-resistant Depression, alongside extensive psychotherapy. ● Clarion Clinics’ built-for-purpo |
|
| January 24, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report January 24, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Ident |
|
| January 24, 2024 |
Exhibit 99.1 Date: January 24, 2024 Public Announcement (NASDAQ: IXHL) Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis MELBOURNE, Australia and NEW YORK, USA, Jan. 24, 2024 (GLOBE NEWSWIRE) - Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing novel medicinal cannabinoid pharmacothe |
|
| January 18, 2024 |
Exhibit 99.1 Date: January 18, 2024 Public Announcement (NASDAQ: IXHL) Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences Highlights: ● 72 patients treated at purpose-built facilities within Monash University, Melbourne, Australia. ● Topline results from the trial anticipated |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report January 18, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Ident |
|
| January 17, 2024 |
Exhibit 99.1 Date: January 17, 2024 Public Announcement (NASDAQ: IXHL) Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea MELBOURNE, Australia and NEW YORK, USA, Jan 17, 2024 (GLOBE NEWSWIRE) - Incannex Healthcare Inc. (Nasdaq: IXHL), (‘Incannex’ or the ‘Company’), a pharmaceutical company developing uniqu |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report January 17, 2024 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Ident |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commiss |
|
| December 22, 2023 |
Exhibit 99.1 Date: December 21, 2023 Public Announcement (NASDAQ: IXHL) CLARION CLINICS RECEIVES ETHICS BOARD ENDORSMENT FOR THE FIRST DEDICATED PSYCHEDELIC-ASSISTED THERAPY CLINIC IN AUSTRALIA Highlights: ● Incannex subsidiary, Clarion Clinics, has received Human Research Ethics Committee (HREC) endorsement for administration of psychedelic-assisted therapies for TRD and PTSD in Australia. ● HREC |
|
| December 20, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) INCANNEX HEALTHCARE INC. |
|
| December 20, 2023 |
As filed with the Securities and Exchange Commission on December 20, 2023 As filed with the Securities and Exchange Commission on December 20, 2023 Registration No. |
|
| December 15, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commiss |
|
| December 15, 2023 |
Exhibit 16.1 December 14, 2023 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Incannex Healthcare Inc. (the “Company”) in the Current Report on Form 8-K dated December 14, 2023. We agree with the statements concerning our Firm in such Form 8-K. However, we are not in a position to a |
|
| November 29, 2023 |
As filed with the Securities and Exchange Commission on November 29, 2023 As filed with the Securities and Exchange Commission on November 29, 2023 Registration No. |
|
| November 29, 2023 |
Exhibit 10.2 Incannex Healthcare Inc. 2023 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Incannex Healthcare Inc. 2023 Equity Incentive Plan is to provide a means through which the Company and its Affiliates may attract and retain key personnel and whereby Directors, Employees, and Consultants of the Company and its Affiliates can acquire and maintain an equity interest in the Company, or b |
|
| November 29, 2023 |
Exhibit 2.1 Deed of Amendment and Restatement between Incannex Healthcare Limited ACN 096 635 246 (Incannex) and Incannex Healthcare Inc. A company incorporated in Delaware, United States of America (US Holdco) DETAILS Date 13 September 2023 Parties Incannex Name Incannex Healthcare Limited ACN 096 635 246 Address Level 23, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000 Email Attention |
|
| November 29, 2023 |
Incannex Healthcare Announces Completion of its Redomiciliation to the United States Exhibit 99.2 Incannex Healthcare Announces Completion of its Redomiciliation to the United States Melbourne November 29, 2023 & New York, November 28, 2023. Incannex Healthcare Inc. (NASDAQ: IXHL) is pleased to announce that its previously announced transaction to redomicile Incannex Healthcare from Australia to the United States has been implemented today, November 28, 2023 New York time (Novembe |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 Incannex Healthcare Inc. (Exact name of registrant as specified in its charter) Delaware 001-41106 93-2403210 (State or other Jurisdiction of Incorporation) (Commiss |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-41106 Incannex Healthcare Limited (Exact name of registrant as specified |
|
| November 29, 2023 |
Exhibit 10.1 Incannex Healthcare Inc. Indemnification Agreement This Indemnification Agreement (this “Agreement”) is dated as of , and is between Incannex Healthcare Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or officers of corporations or in |
|
| November 29, 2023 |
Form 25 |
|
| November 29, 2023 |
Exhibit 14.1 Incannex Healthcare Inc. Code of Conduct 1. Introduction The reputation and integrity of Incannex Healthcare Inc. and its subsidiaries (collectively, the “Company”) are valuable assets that are vital to the Company’s success. Each employee of the Company, including each of the Company’s officers and Directors, is responsible for conducting the Company’s business in a manner that demon |
|
| November 29, 2023 |
Exhibit 3.1 Amended and Restated Certificate of Incorporation of Incannex Healthcare Inc. Incannex Healthcare Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is “Incannex Healthcare Inc.” The original certificate of incorporation of the Corporation was filed with the Secretary of Sta |
|
| November 29, 2023 |
Exhibit 99.1 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Incannex Healthcare Inc., a Delaware corporation (the “Company”) is a summary only. This summary is subject to the General Corporation Law of the State of Delaware (the “DGCL”) and the complete text of the Company’s Certificate of Incorporation and the Bylaws, each as amended and restated. General Under the |
|
| November 29, 2023 |
Exhibit 3.2 Amended and Restated Bylaws of Incannex Healthcare Inc. (a Delaware corporation) Article I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of Incannex Healthcare Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation. Section 1.2 Other Offices. The Corporation may also have an office or offices, and keep the books and recor |
|
| November 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November, 2023 Commission File Number: 001-41106 Incannex Healthcare Limited (Exact name of Registrant as specified in its charter) not applicable (Translation of Registrant’s name into English |
|
| November 24, 2023 |
Computershare Account Opening and Support Information for Shareholders with Australian Addresses Exhibit 99.1 Date: November 23, 2023 Public Announcement (NASDAQ: IXHL) Computershare Account Opening and Support Information for Shareholders with Australian Addresses Melbourne, Australia, 23 November 2023 – Incannex Healthcare Limited (Nasdaq: IXHL) (‘Incannex’ or the ‘Company’) is pleased to confirm that Incannex Healthcare Inc. (‘Incannex US’) has appointed Computershare as its US shareholder |
|
| November 20, 2023 |
Exhibit 99.1 Market Announcement 17 November 2023 Incannex Healthcare Limited (ASX: IHL) – Suspension from Quotation Description The securities of Incannex Healthcare Limited (‘IHL’) will be suspended from quotation at the close of trading on Friday, 17 November 2023 under Listing Rule 17.2, following lodgement of the Federal Court of Australia orders with ASIC approving the scheme of arrangement |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November, 2023 Commission File Number: 001-41106 Incannex Healthcare Limited (Exact name of Registrant as specified in its charter) not applicable (Translation of Registrant’s name into English |
